Induction of apoptosis in breast cancer cells by apomine is mediated by caspase and p38 mitogen activated protein kinase activation

Biochemical and Biophysical Research Communications

Volumn 329, Issue 2, 2005, Pages 772-779

  Lowe, Lorraine C ^a   Senaratne, Siddhika G ^b   Colston, Kay W ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Apomine; Apoptosis; Breast cancer; Caspases; p38 MAPK

Indexed keywords

2 (3,5 DI TERT BUTYL 4 HYDROXYPHENYL) 1,1 ETHANEBISPHOSPHONIC ACID TETRAISOPROPYL ESTER; CASPASE; DNA FRAGMENT; MITOGEN ACTIVATED PROTEIN KINASE P38;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER GROWTH; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME LOCALIZATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 14644422221     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2005.02.032     Document Type: Article

References (20)

1. T.A. Berkhout, H.M. Simon, B. Jackson, J. Yates, N. Pearce, P.H. Groot, C. Bentzen, E.J. Niesor, W.D. Kerns, and K.E. Suckling SR-12813 lowers plasma cholesterol in beagle dogs by decreasing cholesterol biosynthesis Atherosclerosis 133 1997 203 212
2. T.A. Berkhout, H.M. Simon, D.D. Patel, C. Bentzen, E.J. Niesor, B. Jackson, and K.E. Suckling The novel cholesterol-lowering drug SR-12813 inhibits cholesterol synthesis via an increased degradation of 3-hydroxy-3- methylglutaryl-coenzyme A reductase J. Biol. Chem. 271 1996 14376 14382
3. J. Flach, I. Antoni, P. Villemin, C.L. Bentzen, and E.J. Niesor The mevalonate/isoprenoid pathway inhibitor apomine (SR-45023A) is antiproliferative and induces apoptosis similar to farnesol Biochem. Biophys. Res. Commun. 270 2000 240 246
4. C.C Correll, L. Ng, and P.A. Edwards Identification of farnesol as the non-sterol derivative of mevalonic acid required for the accelerated degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase J. Biol. Chem. 269 1994 17390 17393
5. K. Miquel, A. Pradines, and G. Favre Farnesol and geranylgeraniol induce actin cytoskeleton disorganization and apoptosis in A549 lung adenocarcinoma cells Biochem. Biophys. Res. Commun. 225 1996 869 876
6. M.L. Anthony, M. Zhao, and K.M. Brindle Inhibition of phosphatidylcholine biosynthesis following induction of apoptosis in HL-60 cells J. Biol. Chem. 274 1999 19686 19692
7. E.J. Niesor, J. Flach, I. Lopes-Antoni, A. Perez, and C.L. Bentzen The nuclear receptors FXR and LXRα: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases Curr. Pharm. Des. 7 2001 231 259
8. R. Mohan, and R.A. Heyman Orphan nuclear receptor modulators Curr. Top. Med. Chem. 3 2003 1637 1647
9. G.A. Francis, E. Fayard, F. Picard, and J. Auwerx Nuclear receptors and the control of metabolism Annu. Rev. Physiol. 65 2003 261 311
10. G. Lambert, M.J. Amar, G. Guo, H.B.J. Brewer, F.J. Gonzalez, and C.J. Sinal The farnesoid X-receptor is an essential regulator of cholesterol homeostasis J. Biol. Chem. 278 2003 2563 2570
11. M. Makishima, A.Y. Okamoto, J.J. Repa, H. Tu, R.M. Learned, A. Luk, M.V. Hull, K.D. Lustig, D.J. Mangelsdorf, and B. Shan Identification of a nuclear receptor for bile acids Science 284 1999 1362 1365
12. D.S. Alberts, A.V. Hallum III, M. Stratton-Custis, D.J. Garcia, M. Gleason-Guzman, S.E. Salmon, P. Santabarbara, E.J. Niesor, S. Floret, and C.L. Bentzen Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of apomine (SR-45023A), a novel oral bisphosphonate anticancer drug Clin. Cancer Res. 7 2001 1246 1250
13. S.G. Senaratne, G. Pirianov, J.L. Mansi, T.R. Arnett, and K.W. Colston Bisphosphonates induce apoptosis in human breast cancer cell lines Br. J. Cancer 82 2000 1459 1468
14. S.S. Bacus, A.V. Gudkov, M. Lowe, L. Lyass, Y. Yung, A.P. Komarov, K. Keyomarsi, Y. Yarden, and R. Seger Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53 Oncogene 20 2001 147 155
15. H.D. Soule A human cell line from a pleural effusion derived from a breast carcinoma J. Natl. Cancer Inst. 51 1973 1416
16. S.G. Senaratne, J.L. Mansi, and K.W. Colston The bisphosphonate zoledronic acid impairs membrane localisation and induces cytochrome c release in breast cancer cells Br. J. Cancer 86 2002 1479 1486
17. R.M. Huber, K. Murphy, B. Miao, J.R. Link, M.R. Cunningham, M.J. Rupar, P.L. Gunyuzlu, J. Haws, and A. Kassam Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters Gene 290 2002 35 43
18. K.H. Cho, J.Y. Park, J.I. Han, and T.S. Jeong Ligand-binding domain of farnesoid X receptor (FXR) had the highest sensitivity and activity among FXR variants in a fluorescence-based assay Lipids 38 2003 1149 1156
19. C.K. Osborne Steroid hormone receptors in breast cancer management Breast Cancer Res. Treat. 51 1998 227 238
20. D. Rosner, W.W. Lane, and T. Nemoto Differential response to chemotherapy in metastatic breast cancer in relation to estrogen receptor level. Results of a prospective randomized study Cancer 64 1989 6 15